PHARMAUST LTD.

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, PHARMAUST LTD. had revenue of €0 and net profit of -€5.62m

(EUR)	2024	YoY
Revenue	0	100.00%
Gross profit	-1.02k	99.82%
Net profit	-5.62m	48.11%
EBITDA	-5.88m	192.08%

Fundamentals

Metric	Value
Market capitalization	€70.24m
Number of shares	486.64m
52-week high/low	€0.34 - €0.0427
Dividends	No
Beta	1.55
P/E ratio	-5.03
PEG ratio	-0.09
P/B ratio	5.25
P/S ratio	0.00

Company profile

PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for humans and animals. The company develops drugs for the treatment of various cancers, and viral and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug for the treatment of cancer. PharmAust has completed Phase 1 clinical trials with monepantel in human and dog diagnosed with solid tumors, as well as initiated a Phase 2 pilot study in dogs diagnosed with Lymphoma. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. The company has a research agreement with the Walter and Eliza Hall Institute to investigate the effects of MPL upon human T-lymphotrophic virus-1 (HTLV-1) infections in vitro. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.